ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.32 0.37 (2.32%) Market Cap: 2.71 Bil Enterprise Value: 2.20 Bil PE Ratio: 90.67 PB Ratio: 5.23 GF Score: 74/100

ACADIA Pharmaceuticals Inc Discuss The Exclusive Worldwide Licensing Of Trofinetide Call Transcript

Jul 13, 2023 / 08:30PM GMT
Release Date Price: $25.8 (-0.23%)
Operator

Hello, and thank you for standing by. Welcome to ACADIA Pharmaceuticals Conference Call. (Operator Instructions) I would now like to hand the conference over to Jessica Tieszen. Ma'am, you may begin.

Jessica Tieszen

Thank you. Good afternoon, everyone, and thank you for joining us on today's call to discuss ACADIA's expanded agreement with Neuren Pharmaceuticals. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide some opening remarks before turning it over to Brendan Teehan, our Chief Operating Officer, Head of Commercial, to discuss the debut launch. Mark Schneyer, our Chief Financial Officer, will discuss the financial terms of the Neuren agreement as well as review preliminary second quarter net sales and updated guidance.

Steve will finish our prepared remarks with some closing thoughts before opening the call up for your questions. In addition, Doug Williamson, our Head of R&D; and Kathie Bishop, our Head of Rare Disease and external innovation, will be on the call and available for the Q&A

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot